Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EPS (Basic) (2016 - 2026)

Ani Pharmaceuticals' EPS (Basic) history spans 16 years, with the latest figure at $1.24 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 325.45% to $1.24 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5, a 412.5% increase, with the full-year FY2025 number at $3.5, up 436.54% from a year prior.
  • EPS (Basic) hit $1.24 in Q4 2025 for Ani Pharmaceuticals, up from $1.19 in the prior quarter.
  • Over the last five years, EPS (Basic) for ANIP hit a ceiling of $1.24 in Q4 2025 and a floor of -$1.87 in Q4 2021.
  • Historically, EPS (Basic) has averaged -$0.16 across 5 years, with a median of -$0.06 in 2021.
  • Biggest five-year swings in EPS (Basic): plummeted 12800.0% in 2022 and later skyrocketed 1300.0% in 2024.
  • Tracing ANIP's EPS (Basic) over 5 years: stood at -$1.87 in 2021, then surged by 84.49% to -$0.29 in 2022, then surged by 106.9% to $0.02 in 2023, then tumbled by 2850.0% to -$0.55 in 2024, then surged by 325.45% to $1.24 in 2025.
  • Business Quant data shows EPS (Basic) for ANIP at $1.24 in Q4 2025, $1.19 in Q3 2025, and $0.37 in Q2 2025.